Advanced PCOS Relief
Helps normalize ovarian function
- Promotes improved blood sugar regulation and mood
- Supports healthy ovarian function and improves egg quality
- Bioavailable form of folic acid for healthy reproductive, hormonal, heart, and brain function
- Normalizes menstrual cycle
$49.86 — or subscribe and save 20%
Advanced PCOS Relief is a comprehensive product that represents a safe and natural approach to addressing the symptoms and complications of PCOS, such as infertility, blood sugar fluctuations, weight gain, irregular menses, excessive hair growth, and mood imbalances. Polycystic ovarian syndrome (PCOS) is a hormonal disorder affecting 5-10% of women of childbearing age and is the most significant cause of infertility in women. It can also be used by women who do not have PCOS but experience similar hormonal and reproductive problems.
Advanced PCOS Relief contains three key nutrients that have been shown to be effective for managing PCOS: myo-inositol, d-chiro-inositol, and the bioactive form of folic acid, 5-MTHF. Many people lack enough enzymatic activity needed to convert standard folic acid to 5-MTHF, the active, usable form.
Inositol is a “B-vitamin like” nutrient found in many foods including grains and citrus fruit. In recent years, research has uncovered the powerful effects of high doses of this nutrient on regulating the menstrual cycle, supporting the healthy functioning of the ovaries, balancing mood and regulating metabolic factors. Myo- and d-chiro-inositol are two different forms of inositol. Myo-inositol is the most abundant form of inositol in nature; whereas d-chiro-inositol is made by the body from myo-inositol. Each performs different functions in the body, making it imperative to sustain the proper ratio of both molecules. Recent research is showing that a combination of both myo- and d-chiro-inositol is more effective for supporting insulin activity, normal androgen levels, ovarian function, metabolic parameters, and mood balance.
Advanced PCOS Relief provides both myo-inositol and D-chiro-inositol in clinical research backed ratios. It also includes the 5-MTHF form of folic acid to ensure efficacy.
Advanced PCOS Relief helps normalize ovarian function, ovulation, and oocyte quality, and normalizes menstrual cycle irregularities in women with PCOS. Advanced PCOS Relief also improves hormonal and metabolic conditions, and improves insulin sensitivity. In addition, it helps restore pregnancy rates in women under 36 with PCOS who undergo in vitro fertilization.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, mustard, soy, dairy, eggs, fish or shellfish.
Take two capsules two to four times daily with or without food, or as directed by a qualified health care practitioner. Use for a minimum of 12 weeks to see beneficial effects.
To ensure a timely treatment of a serious cause of infertility, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you are pregnant, breastfeeding, or if symptoms persist or worsen.
- Polycystic Ovarian Syndrome
- Glucose management and regulation
- Menstrual symptoms
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Poly Cystic Ovarian Syndrome (PCOS):
This randomized, placebo-controlled clinical study aimed to evaluate the effect of a combination of folic acid, myo-inositol (MI), and D-chiro inositol (DCI) in young overweight women with polycystic ovary syndrome (PCOS), characterized by anovulation and hyperandrogenism, correlated to insulin resistance. Participants received either a placebo or folic acid (200 μg) + MI (550 mg) + DCI (13.8 mg) twice daily for 6 months. At baseline, all patients did not differ significantly and were in the follicular phase of their menstrual cycle. All patients were evaluated for FSH, LH, 17-beta-Estradiol (E), Sex Hormone Binding Globulin (SHBG), androstenedione, free testosterone, and dehydroepiandrosterone sulphate (DHEAS) levels at the baseline and after the six months of therapy.
The results show a statistically significant reduction of LH, free testosterone, fasting insulin, and HOMA index in the combination therapy group, compared to the placebo. Additionally, an increase in 17-beta-Estradiol levels was observed in this group, suggesting that the combination supplementation with MI, DCI, and folate is effective in improving endocrine and metabolic parameters in young overweight women affected by PCOS.
This study describes the effect of inositols supplementation on the metabolic profile of women with a diagnosis of PCOS. This prospective, case-control clinical study enrolled 30 participants – 15 PCOS patients and15 control women and they were supplemented with Myo-inositol (1.75 g per day), D-chiro-inositol (0.25 g per day) and glucomannan, a water-soluble fiber from the konjac root (4 g per day) for three months. Blood concentrations of glucose, insulin, triglycerides, and cholesterol, and ovary volumes and antral follicles count, as well as metabolomic profiles, were evaluated for control subjects and PCOS patients before and after treatment.
At baseline, the PCOS patients had a higher BMI than the control group. Following supplementation, the BMI in the PCOS women decreased significantly. This study also identified metabolites in the PCOS women that were specifically correlated with the diagnosis of PCOS and the therapeutic exposure to inositols. These results suggest that inositol supplementation can improve the metabolomic pathways and metabolic profiles in women with PCOS.
A systematic review and meta-analysis of clinical studies that evaluated the effect of inositol supplementation in women with PCOS were published in 2017. This publication reviewed randomized, controlled studies for the effect of inositols as ovulation induction agents.the meta-analysis included 10 randomized trials, with 362 women on inositol (257 on Myo-inositol and 105 on D-chiro-inositol), 179 women on placebo and 60 were on metformin. The results and analysis show that inositol supplementation was associated with significantly improved ovulation rate and increase the frequency of menstrual cycles, compared with placebo groups. One of the studies reviewed reported increased pregnancy rates in the participants on inositol, compared with placebo groups. The authors conclude that supplementation with inositols improves menstrual cycles, ovulation, and metabolic changes in polycystic ovary syndrome.
Another systematic review evaluated clinical evidence for the effect of inositol supplementation on glucose and insulin sensitivity, 17β-estradiol (E2), testosterone (T), androstenedione (A), the homeostatic model assessment (HOMA) index, sex hormone-binding globulin (SHGB), r-FSH, stimulation days, oocyte quality, embryo quality, biochemical pregnancies, and pregnancy rate. This review draws attention to the importance of the ratio between Myo-inositol and D-chiro inositol supplementation in PCOS. Two of the studies reviewed suggest that deficiencies of these two inositols might be a contributing factor to the pathophysiology of insulin resistance in PCOS patients.
The results conclude that inositol supplementation, particularly MI and DCI contribute to improving several of the hormonal and reproductive disturbances of PCOS; furthermore, the analysis lends prominence to the pivotal role of MI and DCI in enhancing oocyte follicular development and oocyte maturation, as well as in the stimulation and pregnancy outcomes in in-vitro fertilization (IVF) procedures.
As with the previous meta-analysis summary, the importance of the right dose and ratios of Myo-inositol and D-chiro-inositol is a determining factor in the effects observed with supplementation. In this randomized, placebo-controlled clinical study, PCOS patients were randomized into one of 5 groups: a placebo group, and four groups receiving increasing doses of D-chiro-inositol (300, 600, 1200 and 2400 mg) daily for eight weeks. Higher doses of DCI was associated with increased r-FSH and the number of immature oocytes, compared to the lower dose groups and placebo groups. The results suggest that increased DCI dosage is associated with the worsening of oocyte quality and ovarian response. Proper dosage of DCI is essential to the positive response in PCOS patients.
The aim of this prospective, randomized, open-label, multicenter pilot study was to examine the effect of myo-inositol administration on ovarian response and oocytes and embryo quality in non-PCOS patients, undergoing multiple follicular stimulation and in-vitro insemination (IVS) by in-vitro fertilization (IVF). Patients were randomized to receive either folic acid or a combination of folic acid and Myo-inositol for three months prior to follicular stimulation by r-FSH (150 IU per day for 6 days). The results showed that the total amount of gonadotropins needed to reach follicular maturation was significantly lower in the myo-inositol supplemented group. Additionally, the number of oocytes retrieved was significantly lower in this group. The results suggest that supplementation with Myo-inositol and folic acid in non-PCOS patients may reduce the numbers of mature oocytes and dosage for follicular stimulation while maintaining pregnancy rates in non-PCOS patients undergoing stimulation for IVF.
PCOS is usually associated with impaired glucose tolerance and a defect in the insulin-signaling pathway. These patients are also considered “sub-fertile” and usually require medication for ovulation induction. The aim of this study was to examine the effect of myo-inositol supplementation on the improvement of insulin-receptor activity and the restoration of normal ovulatory function. Twenty-five PCOS women of childbearing age with oligo- or amenorrhea were enrolled in the study. Ovulatory disorder due to PCOS was apparently the only cause of infertility. Participants were supplemented with 2 g twice daily of myo-inositol and folic acid for six months, during which time, ovulatory activity was monitored.
The results suggest that Myo-inositol and folic acid supplementation was associated with restored spontaneous menstrual cycles, 72% of which maintained normal ovulatory activity. 40% of the patients got pregnant during the study. These results suggest that inositol and folic acid supplementation could help restore spontaneous ovarian activity and consequently fertility in PCOS patients.
Myo-inositol (MI) and D-chiro-inositol (DCI), individually and in combination, are considered insulin-sensitizing agents, especially when given to patients with PCOS, suffering from infertility. The aim of this study was to compare the effects of MI and DCI on oocyte quality, as a marker of improved fertility in PCOS patients with normal glucose levels. All patients treated in the in vitro fertilization (IVF) Department of the researchers of infertility for a period of more than 12 months were asked to participate in the study. 43 patients received 2 g MI twice daily, while the other 43 patients received 0.6 g DCI twice a day for eight weeks before follicle-stimulating hormone (rFSH) administration.
The results of this study showed no significant difference between both groups on the total number of oocytes retrieved, however, the number of mature oocytes, mean number of top-quality embryos, and total number of pregnancies was significantly higher in the group receiving myo-inositol.
Glucose Management/Metabolic Syndrome:
The aim of this study was to evaluate the effect of supplementation with myo-inositol on biochemical parameters of women affected by metabolic syndrome. Eighty post-menopausal patients were recruited for this 12-month study and randomly assigned to either a placebo group or Myo-inositol (2 g twice daily). All participants were assessed for serum glucose, insulin, HOMA-IR (Homeostasis Model Assessment-Insulin Resistance), triglycerides, total and high-density lipoprotein cholesterol, body mass index (BMI), waist circumference and blood pressure at baseline and after 12 months of treatment.
The results show that supplementation with Myo-inositol was associated with significant improvement all but BMI and waist circumference parameters. Myo-inositol supplementation helped reduce the number of women with metabolic syndrome over the duration of the study.
Gestational diabetes is associated with poor pregnancy outcomes and could have negative effects on both mother and child. The aim of this study was to evaluate the effect of myo-inositol supplementation on the onset of gestational diabetes in pregnant women with a familial history of type 2 diabetes. This prospective, randomized, open-label, placebo-controlled clinical study recruited 220 pregnant women, who were randomized to receive either a placebo and folic acid (200 μg) or myo-inositol (2 g) and folic acid (200 μg) twice a day, starting in the first trimester. The researchers assessed all participants for the following: the incidence of gestational diabetes and fetal macrosomia, gestational hypertension, pre-term delivery, cesarean section, shoulder dystocia, neonatal hypoglycemia, and neonatal distress respiratory syndrome.
The results show a significantly reduced incidence of gestational diabetes, fetal macrosomia, and mean fetal weight in the myo-inositol supplemented group, compared to the placebo group.
A similar study, also published in 2013 showed similar effects of myo-inositol supplementation on reduction in the incidence of gestational diabetes and improved pregnancy outcomes https://www.ncbi.nlm.nih.gov/pubmed/23327487.
A systematic review and meta-analysis of 4 randomized, controlled studies including 567 women confirmed the role of myo-inositol supplementation in reducing gestational diabetes incidence https://www.ncbi.nlm.nih.gov/pubmed/26678256.
In this randomized, controlled trial, researchers aimed to assess the effect of D-chiro-inositol and folic acid supplementation on glucose control and insulin resistance in overweight/obese patients with type I diabetes. Participants were randomized to receive either 400 μg folic acid daily (control) or a combination of folic acid (400 μg) and DCI (1000 mg) once daily and assessed for HbA1C, as a marker of blood sugar levels, as well as BMI and insulin requirement.
DCI and folic acid supplementation led to a significant reduction in HbA1C levels, compared to the control group, suggesting that DCI and folic acid supplementation can improve metabolic control in overweight patients with type I diabetes.
This prospective, randomized, placebo-controlled study aimed to evaluate the effect of myo-inositol supplementation in improving features of metabolic syndrome in postmenopausal women with metabolic syndrome. Participants were randomized to receive either a placebo or myo-inositol (2 g twice a day) for 6 months. Each group was also on a restricted diet for the duration of the study.
The results indicate that myo-inositol supplementation improved systolic and diastolic blood pressure, HOMA index (as a measure of insulin resistance), cholesterol, and triglyceride serum levels, compared to the placebo group, providing sufficient evidence for the use of Myo-inositol supplementation in post-menopausal women with metabolic syndrome.
Q: Are high doses of inositol safe?
A: Inositol is extremely safe. Still, it is important to slowly and gradually increase the dose in some individuals in order to prevent the unwanted side effect of diarrhea. While this is a relatively rare concern, it is one that people tend to want to avoid.
Customers also bought
You may also like…
Advanced B Complex Ultra
Award-winning formula plus brain support, in a time-release tablet
- All the benefits of our Advanced B Complex®, plus brain support
- Time-release formula allows for improved absorption
- Optimal doses of the most effective and biologically active forms of B vitamins
- Antioxidant PQQ for support of cardiovascular, cognitive health and energy
- Three types of B12
- Time-release minimizes niacin “flush”